Wed, 05/09/2018 - 17:30 Regulatory

Bulletin from Swedish Orphan Biovitrum’s (publ) (“Sobi’s”) Annual General Meeting (AGM)

The Sobi AGM was convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability

The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,486,594,396.

The board members and the chief executive officers were discharged from liability for the financial year 2017.

Election of Board of Directors, remuneration to the Directors and election of Auditor

The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Schikan were re-elected and David Allsop and Elisabeth Svanberg were elected as new board members for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.

Mr. Allsop was born in 1963 and has a BSc Hons Chemistry from Coventry University, UK. Through his company U-R-NOT Ltd., Mr Allsop offers advisory services to the pharma industry. He has international experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Further, Mr. Allsop has experience from successfully launching blockbuster biologics across the entire world. Until January 2018, he was Head of International in Amicus Therapeutics Ltd. Before then Mr. Allsop held a number of senior positions in Biogen 1998–2015.

Ms. Svanberg was born 1961 and has a MD and PhD from the University of Gothenburg, Sweden. Ms. Svanberg is associate professor of surgery and is serving as Chief Development Officer at Ixaltis SA since 2016. She is member of the Board of Directors of Follicum AB and PledPharma AB, and has also served as board member of the Swedish American Chamber of Commerce New York. Previously she was Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016 and has worked with Bristol Myers Squibb (BMS) in the US leading the development of a novel diabetes medicine and subsequently served as Head of Medical Affairs for the Intercontinental region. 2000–2007, Ms. Svanberg worked at Serono International in the field of metabolism.

The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.

Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.

Principles for remuneration for the management, long-term incentive programme, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares

The AGM approved the guidelines for remuneration for the management proposed by the Board.

The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive programme, and hedging arrangements in respect of the programme including a directed issue of no more than 814,409 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,427,269 own common shares to programme participants.

The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.

The Board’s proposal regarding transfer of no more than 144,808 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Programme 2015, was also approved by the AGM.

For full details on each proposal adopted by the AGM, please refer to www.sobi.com.

----

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing innovative treatments that transform life for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact 

Media relations
Linda Holmström, Senior Communications Manager
+46 708 734 095
linda.holmstrom@sobi.com 

The information was released for public distribution on 9 May, 2018 at 17:30 CET.